

Tigecycline Catalog No: tcsc1876

Available Sizes

Size: 10mg

Size: 50mg

Size: 200mg

Size: 500mg

Size: 500mg

Size: 500mg

CAS No:
220620-09-7

Formula:

C₂₉H₃₉N₅O₈

Pathway: Anti-infection;Autophagy

Target: Bacterial;Autophagy

Purity / Grade:

>98%

Solubility:

DMSO : 155 mg/mL (264.66 mM; Need ultrasonic)

Alternative Names:

GAR-936

Copyright 2021 Taiclone Biotech Corp.



Observed Molecular Weight:

585.65


Product Description

Tigecycline is a first-in-class, broad spectrum antibiotic with activity against antibiotic-resistant organisms.

Target: Antibacterial

Tigecycline is active against a broad range of gram-negative and gram-positive bacterial species including clinically important multidrug-resistant nosocomial and community-acquired bacterial pathogens. Tigecycline has been shown to inhibit the translation elongation step by binding to the ribosome 30S subunit and preventing aminoacylated tRNAs to accommodate in the ribosomal A site [1]. Tigecycline has also been found to be effective for the treatment of community- as well as hospital-acquired and ventilator-associated pneumonia and bacteremia, sepsis with shock and urinary tract infections. Tigecycline appears to be a valuable treatment option for the management of superbugs, especially where conventional therapy has failed [2].

Fifteen patients received tigecycline for 16 episodes of CPKP infection. The main infections were pneumonia (31%), urinary tract infection (31%), peritonitis (20%), catheter-related bacteraemia (12%), and meningitis (6%). Most infections were complicated with severe sepsis (44%), septic shock (12%), and/or bacteraemia (19%). The daily maintenance dose of tigecycline was 200 mg in 10 episodes and 100 mg in 6 episodes. The overall 30-day mortality rate was 25%. Univariate analysis showed that mortality was significantly associated (p



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.